DUBLIN, Ireland, July 1, 2013 (GLOBE NEWSWIRE) -- Prothena Corporation plc. (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases, announced that Dale Schenk, PhD, the Company's President and Chief Executive Officer, will be presenting at the Eighth Annual JMP Securities Healthcare Conference on Wednesday, July 10, 2013, at 10:30 AM ET. The conference will be held at the St. Regis in New York.
A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a reply of the webcast will be available on the Company's website for 90 days.
Prothena Corporation plc is a clinical stage biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding and cell adhesion, particularly on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease-causing proteins. These potential therapies have a broad range of indications, including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and related synucleinopathies (PRX002) and novel cell adhesion targets involved in inflammatory disease and metastatic cancers (PRX003).
For more information, please visit the Company's web site at www.prothena.com.